We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

63 hedge funds and large institutions have $90.1M invested in Orchestra BioMed in 2025 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

333% more call options, than puts

Call options by funds: $329K | Put options by funds: $76K

320% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 5

61% more capital invested

Capital invested by funds: $56.1M → $90.1M (+$34M)

21% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 14

21% more funds holding

Funds holding: 52 → 63 (+11)

3.99% less ownership

Funds ownership: 42.42% → 38.43% (-4%)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
63
Holders Change
+11
Holders Change %
+21.15%
% of All Funds
0.77%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
21
Increased
17
Reduced
14
Closed
5
Calls
$329K
Puts
$76K
Net Calls
+$253K
Net Calls Change
+$375K

Top Buyers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
+$823K
2
Marshall Wace
Marshall Wace
United Kingdom
+$693K
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$653K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$495K
5
Goldman Sachs
Goldman Sachs
New York
+$446K

Top Sellers

Rank Fund Capital Flow
1
Pathstone Holdings
Pathstone Holdings
New Jersey
-$2.49M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.47M
3
DCM
DAFNA Capital Management
California
-$955K
4
Renaissance Technologies
Renaissance Technologies
New York
-$925K
5
PA
Perceptive Advisors
New York
-$667K
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$359K +$349K +86,552 New
Morgan Stanley
27
Morgan Stanley
New York
$340K +$289K +71,528 +693%
OAC
28
OMERS Administration Corp
Ontario, Canada
$278K +$271K +67,100 New
HIW
29
Holos Integrated Wealth
Pennsylvania
$222K – – –
XT
30
XTX Topco
Cayman Islands
$209K +$62.7K +15,540 +45%
Hudson Bay Capital Management
31
Hudson Bay Capital Management
Connecticut
$205K +$199K +49,425 New
TD Asset Management
32
TD Asset Management
Ontario, Canada
$190K -$190K -46,986 -51%
Squarepoint
33
Squarepoint
New York
$184K +$179K +44,343 New
NA
34
NewEdge Advisors
Louisiana
$183K – – –
Manulife (Manufacturers Life Insurance)
35
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$135K – – –
Citadel Advisors
36
Citadel Advisors
Florida
$125K -$96.1K -23,827 -44%
MFP
37
Meramec Financial Planners
Missouri
$117K +$121K +30,000 New
Two Sigma Advisers
38
Two Sigma Advisers
New York
$112K +$109K +27,100 New
BCM
39
Bridgeway Capital Management
Texas
$104K – – –
LIP
40
Lighthouse Investment Partners
Florida
$103K +$100K +24,900 New
DSC
41
Daytona Street Capital
Missouri
$89.2K +$86.7K +21,500 New
CAM
42
Cresset Asset Management
Illinois
$83K +$80.7K +20,000 New
Citigroup
43
Citigroup
New York
$80.8K +$78.3K +19,417 +47,359%
HighTower Advisors
44
HighTower Advisors
Illinois
$75.8K – – –
Balyasny Asset Management
45
Balyasny Asset Management
Illinois
$75.8K +$73.7K +18,268 New
Bank of America
46
Bank of America
North Carolina
$72.8K -$54.8K -13,572 -44%
BNP Paribas Financial Markets
47
BNP Paribas Financial Markets
France
$70.6K +$66.3K +16,443 +2,915%
AQR Capital Management
48
AQR Capital Management
Connecticut
$67.6K -$3.32K -822 -5%
Creative Planning
49
Creative Planning
Kansas
$67.6K -$3.27K -811 -5%
VF
50
Virtu Financial
New York
$57K +$55K +13,623 New
1
2
3

OBIO Hedge Fund Activity: Q4 2025 in Review

63 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q4 2025, worth a combined $90.1M — up 61% from $56.1M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new OBIO positions and 5 closed out — a net gain of 16 holders — while 17 added to existing stakes and 14 trimmed.

The largest buyer was 683 Capital Management, opening a new position worth an estimated $823K. The largest seller was Pathstone Holdings, exiting entirely with an estimated $2.49M sold.

  • 63 institutional investors held Orchestra BioMed (OBIO) as of Q4 2025, up from 52 in Q3 2025.
  • Funds reported $90.1M of Orchestra BioMed stock for Q4 2025, up 61% quarter-over-quarter.
  • 21 funds opened new Orchestra BioMed positions in Q4 2025 and 5 closed out, a net change of +16 holders.
  • The largest Orchestra BioMed buyer in Q4 2025 was 683 Capital Management, an estimated $823K added.
  • The largest Orchestra BioMed seller in Q4 2025 was Pathstone Holdings, an estimated $2.49M sold.

Based on aggregated 13F filings for Q4 2025.